Currently, three generations of BCR–ABL inhibitors have been approved to treat CML, mainly including Imatinib (Gleevec), Nilotinib, and Ponatinib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.